PL2509602T3 - Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2 - Google Patents

Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2

Info

Publication number
PL2509602T3
PL2509602T3 PL10834934T PL10834934T PL2509602T3 PL 2509602 T3 PL2509602 T3 PL 2509602T3 PL 10834934 T PL10834934 T PL 10834934T PL 10834934 T PL10834934 T PL 10834934T PL 2509602 T3 PL2509602 T3 PL 2509602T3
Authority
PL
Poland
Prior art keywords
pyrazolopyrimidines
inhibitors
related heterocycles
heterocycles
Prior art date
Application number
PL10834934T
Other languages
English (en)
Polish (pl)
Inventor
Mustapha Haddach
Joe A. Tran
Fabrice Pierre
Collin F. Regan
Nicholas B. Raffaele
Suchitra Ravula
David M. Ryckman
Original Assignee
Senhwa Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences, Inc. filed Critical Senhwa Biosciences, Inc.
Publication of PL2509602T3 publication Critical patent/PL2509602T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL10834934T 2009-12-04 2010-11-15 Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2 PL2509602T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26680109P 2009-12-04 2009-12-04
US35416510P 2010-06-11 2010-06-11

Publications (1)

Publication Number Publication Date
PL2509602T3 true PL2509602T3 (pl) 2017-08-31

Family

ID=44115232

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10834934T PL2509602T3 (pl) 2009-12-04 2010-11-15 Pirazolopirymidyny i podobne heterocykle jako inhibitory ck2

Country Status (14)

Country Link
US (2) US8575177B2 (cg-RX-API-DMAC7.html)
EP (1) EP2509602B9 (cg-RX-API-DMAC7.html)
JP (1) JP5802676B2 (cg-RX-API-DMAC7.html)
KR (1) KR101851130B1 (cg-RX-API-DMAC7.html)
CN (1) CN102762208A (cg-RX-API-DMAC7.html)
AU (1) AU2010326268B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012013508A2 (cg-RX-API-DMAC7.html)
CA (1) CA2782684C (cg-RX-API-DMAC7.html)
ES (1) ES2629170T3 (cg-RX-API-DMAC7.html)
IL (1) IL220086B (cg-RX-API-DMAC7.html)
PL (1) PL2509602T3 (cg-RX-API-DMAC7.html)
RU (1) RU2607453C2 (cg-RX-API-DMAC7.html)
SG (1) SG181507A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011068667A1 (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2555261T3 (es) * 2010-06-01 2015-12-30 Bayer Intellectual Property Gmbh Imidazopirazinas sustituidas
EP2575818A4 (en) 2010-06-03 2013-11-06 Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE INHIBITORS (BTK)
WO2012170827A2 (en) * 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
EP2723746A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
WO2013161567A1 (ja) * 2012-04-27 2013-10-31 新日鐵住金株式会社 継目無鋼管及びその製造方法
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
TW201414737A (zh) * 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
JP6575950B2 (ja) 2012-07-24 2019-09-18 ファーマサイクリックス エルエルシー Ｂｒｕｔｏｎ型チロシンキナーゼ（Ｂｔｋ）阻害剤に対する耐性を伴う変異
EP4534538A3 (en) 2012-12-07 2025-06-11 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
AR094664A1 (es) 2013-01-15 2015-08-19 Incyte Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US8969360B2 (en) 2013-03-15 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2014143241A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
CN103360399B (zh) * 2013-08-02 2016-03-02 北京大学 6-芳基取代-咪唑-[1,2-b]哒嗪类衍生物，其制备方法及用途
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
CN103570728B (zh) * 2013-11-12 2015-12-30 山东大学 一种取代吡唑并[1,5-a]嘧啶类衍生物及其制备方法与应用
CA2932757C (en) 2013-12-06 2023-10-31 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
ES2702126T3 (es) * 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
TWI534148B (zh) * 2014-02-13 2016-05-21 生華生物科技股份有限公司 吡唑並嘧啶前藥及其使用方法
GB201403093D0 (en) * 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN106170489B (zh) * 2014-05-28 2019-05-03 诺华股份有限公司 新的吡唑并嘧啶衍生物及其作为malt1抑制剂的用途
RU2719583C2 (ru) 2014-06-05 2020-04-21 Вертекс Фармасьютикалз Инкорпорейтед Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор-пиридин-3-ил]-пиразоло[1, 5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
CN105457029A (zh) * 2014-09-29 2016-04-06 中国科学院上海巴斯德研究所 抑制酪蛋白激酶2活性在促进i型干扰素表达的应用
JP2017537940A (ja) * 2014-12-10 2017-12-21 マサチューセッツ インスティテュート オブ テクノロジー 増殖性疾患の処置に有用な融合１，３−アゾール誘導体
CA2973432C (en) * 2015-01-23 2023-04-04 Glaxosmithkline Intellectual Property Development Limited Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
KR102678021B1 (ko) 2015-09-30 2024-06-26 버텍스 파마슈티칼스 인코포레이티드 Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
KR20180107261A (ko) 2016-02-16 2018-10-01 메사추세츠 인스티튜트 오브 테크놀로지 Myc 조정제로서의 MAX 결합제 및 그의 용도
CN109562111B (zh) * 2016-06-24 2023-04-04 北极星药业股份有限公司 Ck2抑制剂，其组合物及方法
AU2018256459B2 (en) 2017-04-21 2023-12-07 Ikena Oncology, Inc. Indole AHR inhibitors and uses thereof
CN107188901A (zh) * 2017-05-27 2017-09-22 无锡捷化医药科技有限公司 一种(3‑(3‑(二甲氨基)丙氧基)苯基)硼酸的制备方法
BR112020001278A2 (pt) 2017-07-28 2020-07-21 Yuhan Corporation processo aprimorado para preparar derivados de aminopirimidina
EP3658557B1 (en) 2017-07-28 2024-06-05 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
GB201715194D0 (en) 2017-09-20 2017-11-01 Carrick Therapeutics Ltd Compounds and their therapeutic use
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
JP7385658B2 (ja) 2018-10-30 2023-11-22 クロノス バイオ インコーポレイテッド Ｃｄｋ９活性を調節するための化合物、組成物、および方法
CN112500416B (zh) * 2019-07-30 2021-12-17 厦门宝太生物科技股份有限公司 一种吡唑并三嗪类化合物中间体的制备方法
EP4065582B1 (en) 2019-11-26 2025-02-19 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
GB201918541D0 (en) 2019-12-16 2020-01-29 Carrick Therapeutics Ltd Therapeutic compounds and their use
KR102337404B1 (ko) * 2020-01-03 2021-12-10 연세대학교 산학협력단 조직 재생용 조성물
JP2023520883A (ja) * 2020-03-30 2023-05-22 センホア・バイオサイエンシーズ・インコーポレイテッド Ｒｎａウイルス感染症、特にｃｏｖｉｄ－１９を処置するための抗ウイルス化合物および方法
CN116323569A (zh) * 2020-09-15 2023-06-23 田边三菱制药株式会社 三嗪化合物的盐、其晶型及制造方法
CA3172939A1 (en) * 2021-01-09 2022-07-14 Bugworks Research, Inc. Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2a receptor and adenosine 2b receptor antagonist
US12343421B2 (en) * 2021-11-01 2025-07-01 Solaana MD LLC Vitamin D base layer
WO2024187126A1 (en) * 2023-03-09 2024-09-12 Aquinnah Pharmaceuticals, Inc. Inhibitors of tdp-43 and tau aggregation
US12269826B1 (en) * 2023-11-16 2025-04-08 King Faisal University 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US7071218B2 (en) * 2001-11-15 2006-07-04 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases
US7206308B2 (en) * 2001-12-22 2007-04-17 International Business Machines Corporation Method of providing a non-blocking routing network
JP2005530739A (ja) * 2002-04-19 2005-10-13 セルラー ジェノミクス，インコーポレーテッド イミダゾ［１，２−ａ］ピラジン−８−イルアミン、生成方法、および使用方法
WO2004006916A1 (en) * 2002-07-10 2004-01-22 Applied Research Systems Ars Holding Nv Use of compounds for increasing spermatozoa motility
PL374718A1 (en) * 2002-07-10 2005-10-31 Applied Research Systems Ars Holding N.V. Azolidinone-vinyl fused-benzene derivatives
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
CA2497544C (en) * 2002-09-04 2010-11-02 Schering Corporation Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
AU2003225669A1 (en) * 2002-09-26 2004-04-19 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
MXPA05008955A (es) * 2003-02-28 2006-02-22 Teijin Pharma Ltd Derivados de pirazolo [1,5-a] pirimidina.
PE20051128A1 (es) * 2004-02-25 2006-01-16 Schering Corp Pirazolotriazinas como inhibidores de quinasa
US7842698B2 (en) * 2004-09-03 2010-11-30 Merck Serono S.A. Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors
EP2046333A4 (en) * 2006-07-24 2010-09-15 Glaxosmithkline Llc THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
FR2907120B1 (fr) * 2006-10-12 2013-01-11 Sanofi Aventis Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7
CN101981033B (zh) * 2008-02-06 2015-02-04 百时美施贵宝公司 用作激酶抑制剂的取代的咪唑并哒嗪化合物
MX2011012369A (es) * 2009-05-20 2012-03-16 Cylene Pharmaceuticals Inc Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa.

Also Published As

Publication number Publication date
RU2012127792A (ru) 2014-08-10
IL220086A0 (en) 2012-09-24
ES2629170T3 (es) 2017-08-07
BR112012013508A2 (pt) 2019-09-24
SG181507A1 (en) 2012-07-30
US9303033B2 (en) 2016-04-05
AU2010326268B2 (en) 2016-11-03
EP2509602A1 (en) 2012-10-17
US20110152240A1 (en) 2011-06-23
EP2509602B9 (en) 2017-11-01
JP5802676B2 (ja) 2015-10-28
US20140094448A1 (en) 2014-04-03
WO2011068667A1 (en) 2011-06-09
EP2509602B1 (en) 2017-01-25
EP2509602A4 (en) 2013-10-09
CN102762208A (zh) 2012-10-31
IL220086B (en) 2018-02-28
JP2013512903A (ja) 2013-04-18
AU2010326268A1 (en) 2012-07-26
CA2782684A1 (en) 2011-06-09
RU2607453C2 (ru) 2017-01-10
KR20130067486A (ko) 2013-06-25
CA2782684C (en) 2018-09-04
US8575177B2 (en) 2013-11-05
KR101851130B1 (ko) 2018-04-23

Similar Documents

Publication Publication Date Title
IL220086A0 (en) Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
ZA201108622B (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors
ZA201101586B (en) Aminotriazolopyridines and their use as kinase inhibitors
IL219646A0 (en) Novelnaphthyridine derivatives and the use thereof as kinase inhibitors
IL222176B (en) Radioprotector compounds and methods
IL218555A0 (en) Pi3 kinase inhibitors and uses thereof
ZA201107717B (en) Imidazopyrazines for use kinase inhibitors
ZA201206257B (en) N-(imidazopyrimidin-7yl)-heteroarylamide derivatives and their use as pde10a inhibitors
ZA201301120B (en) Heterocyclic compound and use thereof
IL210055A0 (en) Thiophene or thiazole derivatives and their use as pi3k inhibitors
EP2387572A4 (en) PROTEIN KINASE C HEMMER AND ITS USE
GB201016880D0 (en) Phosphodiesterase inhibitors
SG173666A1 (en) Isoxazole-isoxazole and isoxazole-isothiazole derivatives
ZA201208948B (en) Modified beta-lactamases and methods and uses related thereto
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
ZA201300036B (en) Banzamide derivatives and their use as hsp90 inhibitors
SG10201507362TA (en) Novel Regulatory Proteins And Inhibitors
IL207127A0 (en) Aldh-2 inhibitors in the treatment of addiction
GB201211237D0 (en) CDK5 inhibitors and therapeutic uses thereof
EP2496230A4 (en) INHIBITORS OF IRE-1 ALPHA
PT2714669T (pt) Hipertensão e hiperuricemia
GB0902173D0 (en) Compounds and their use
GB0922510D0 (en) Compound and use
IL230746A0 (en) 2-aldh inhibitors in the treatment of addiction
EP2470022A4 (en) COMPOUNDS AND METHODS